Table 1.
Baseline characteristics of overall cohort.
| Lung Cancer (n = 313) | Other Solid Tumor (n = 1578) | Hematological Malignancy (n = 474) | |
|---|---|---|---|
| Age | |||
| Mean (median) | 66.6 (22–93) | 64.0 (20–101) | 63.1 (21–92) |
| Gender | |||
| Female | 187 (59.7%) | 676 (42.8%) | 224 (47.3%) |
| Male | 126 (40.3%) | 902 (57.2%) | 250 (52.7%) |
| Site | |||
| MSSM | 103 (32.9%) | 946 (59.9%) | 454 (95.8%) |
| DFCI | 210 (67.1%) | 632 (40.1%) | 20 (4.2%) |
| Race/Ethnicity | |||
| Non-Hispanic White | 205 (65.5%) | 899 (57.0%) | 242 (51.1%) |
| Non-Hispanic Black | 28 (8.9%) | 198 (12.5%) | 73 (15.4%) |
| Hispanic | 25 (8.0%) | 194 (12.3%) | 78 (16.5%) |
| Other | 24 (7.7%) | 114 (7.2%) | 29 (6.1%) |
| Unknown | 31 (9.9%) | 173 (11.0%) | 52 (11.0%) |
| Tobacco Use | |||
| Current/prior use | 226 (72.2%) | 707 (44.8%) | 176 (37.1%) |
| Tumor Status | |||
| CR or NED | 15 (4.8%) | 327 (20.7%) | 146 (30.8%) |
| Local, LA, or stable | 88 (28.1%) | 590 (37.4%) | 137 (28.9%) |
| Metastatic or active | 205 (65.5%) | 623 (39.5%) | 188 (39.7%) |
| Other or unknown | 5 (1.6%) | 38 (2.4%) | 3 (0.6%) |
| Receiving Systemic Therapy at Index Visit | |||
| Yes | 209 (66.8%) | 999 (63.3%) | 276 (58.2%) |
CR: complete response; NED: no evidence of disease; LA: locally advanced.